利用整合入肝细胞癌细胞基因组的HBV-DNA表达谱筛选用于免疫治疗的T细胞
研究探讨了HBV相关肝细胞癌中整合的HBV-DNA片段是否编码可被T细胞识别的表位,并据此从既往自限性HBV感染患者中筛选特异性T细胞受体(TCR),经电转染mRNA改造自体T细胞后过继回输给2例肝移植后复发患者,未观察到明显不良事件;1例患者6个肺转移灶中5个在1年回输期内体积缩小。
要点
- 不表达完整HBV抗原的HCC细胞仍含短HBV mRNA,可编码被HBV特异性T细胞识别的表位。
- 根据转移灶HBV转录谱从TCR库中筛选特异性TCR,改造自体T细胞后回输2例患者,未出现明显不良事件。
- 1例患者6个肺转移灶中5个在1年T细胞回输期间体积缩小。
核心结论
- HCC细胞含整合HBV-DNA短片段,可编码被T细胞识别并激活T细胞的表位。
- 这些细胞的HBV转录组可用于改造T细胞进行个体化免疫治疗。
- 该方法可能用于治疗更广泛的HBV相关HCC患者。
研究设计与样本
- 基础与转化研究:分析HCC细胞中HBV mRNA及表位,并利用2例肝移植后复发HCC患者的原发灶和转移灶HBV基因表达谱筛选TCR。
- 对2例患者进行自体TCR改造T细胞过继回输,每周递增剂量1×10^4至10×10^6 TCR+ T细胞/kg,持续112天或1年。
主要发现
- 经免疫组化HBV抗原阴性的HCC细胞含短HBV mRNA,可编码被HBV特异性T细胞识别并激活的表位。
- 2例患者接受针对转移灶HBV-DNA编码表位的自体TCR T细胞回输,未出现明显不良事件。
- 回输1年内未影响肝功能。
- 1例患者6个肺转移灶中5个在1年T细胞回输期间体积缩小。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is often associated with hepatitis B virus (HBV) infection. Cells of most HBV-related HCCs contain HBV-DNA fragments that do not encode entire HBV antigens. We investigated whether these integrated HBV-DNA fragments encode epitopes that are recognized by T cells and whether their presence in HCCs can be used to select HBV-specific T-cell receptors (TCRs) for immunotherapy. METHODS: HCC cells negative for HBV antigens, based on immunohistochemistry, were analyzed for the presence of HBV messenger RNAs (mRNAs) by real-time polymerase chain reaction, sequencing, and Nanostring approaches. We tested the ability of HBV mRNA-positive HCC cells to generate epitopes that are recognized by T cells using HBV-specific T cells and TCR-like antibodies. We then analyzed HBV gene expression profiles of primary HCCs and metastases from 2 patients with HCC recurrence after liver transplantation. Using the HBV-transcript profiles, we selected, from a library of TCRs previously characterized from patients with self-limited HBV infection, the TCR specific for the HBV epitope encoded by the detected HBV mRNA. Autologous T cells were engineered to express the selected TCRs, through electroporation of mRNA into cells, and these TCR T cells were adoptively transferred to the patients in increasing numbers (1 × 104-10 × 106 TCR+ T cells/kg) weekly for 112 days or 1 year. We monitored patients' liver function, serum levels of cytokines, and standard blood parameters. Antitumor efficacy was assessed based on serum levels of alpha fetoprotein and computed tomography of metastases. RESULTS: HCC cells that did not express whole HBV antigens contained short HBV mRNAs, which encode epitopes that are recognized by and activate HBV-specific T cells. Autologous T cells engineered to express TCRs specific for epitopes expressed from HBV-DNA in patients' metastases were given to 2 patients without notable adverse events. The cells did not affect liver function over a 1-year period. In 1 patient, 5 of 6 pulmonary metastases decreased in volume during the 1-year period of T-cell administration. CONCLUSIONS: HCC cells contain short segments of integrated HBV-DNA that encodes epitopes that are recognized by and activate T cells. HBV transcriptomes of these cells could be used to engineer T cells for personalized immunotherapy. This approach might be used to treat a wider population of patients with HBV-associated HCC.
引用
- Tan AT, Yang N, Lee Krishnamoorthy T, et al. Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy. Gastroenterology. 2019. PMID: 30711630. doi:10.1053/j.gastro.2019.01.251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。